The "14th Five-Year Plan" pharmaceutical industry development path has seven goals to understand


Release time:

2020-12-28

On December 20th, at the 13th China Pharmaceutical Strategy Conference "Pharmaceutical Industry Hotspot Policy Forum" co-sponsored by the China Pharmaceutical Industry Information Center and the Central Youth Working Committee of the Peasants and Workers Party, relevant persons from the Consumer Goods Industry Department of the Ministry of Industry and Information Technology Introduced the relevant situation of the "14th Five-Year Plan" of the pharmaceutical industry. It is reported that during the "14th Five-Year Plan" period, my country's pharmaceutical industry must achieve the seven major goals of initially forming an innovation-driven development model, solving a number of neck problems as soon as possible, and some pharmaceutical companies entering the forefront of global pharmaceutical companies.

Specifically, the seven goals are:

First, an innovation-driven development model has been initially formed. The average intensity of R & D investment of listed companies in the pharmaceutical industry has increased significantly. The number of newly listed innovative drugs and approved innovative drugs in developed countries in Europe and the United States has increased, and more new products and new technologies have been used to drive industrial growth.. The key task is to lay out the original innovation, speed up the integration of technology, improve the innovation system, build a support platform, cultivate innovative enterprises and so on.

Second, the supply guarantee capacity has been further improved, the national supply guarantee capacity of essential drugs has been strengthened, the shortage of clinical drugs has been systematically improved, the number of rare disease treatment drugs has increased significantly, the national medical reserve system has been further improved, and the emergency research and development and emergency production capacity in response to major disasters, epidemics or their emergencies have been significantly enhanced.. The key tasks are to improve the emergency response mechanism, optimize the emergency review and approval process, strengthen emergency research and development and production capacity, strengthen the reserve of drugs and medical protection materials, and increase medical facilities for epidemic prevention and treatment.

The third is to improve the modernization level of the industrial chain supply chain, further coordinate and advance, make up for shortcomings and forge long boards, solve a number of neck problems as soon as possible, and work intensively in the industrial advantage areas to form a stronger innovation, higher added value, and more Safe and reliable industrial chain supply chain. The key tasks are to do a good job in supply chain strategic design and precise policy implementation; maintain the competitive advantage of API products, promote key enterprises to achieve breakthroughs in drug design, production technology, high-end excipients, pharmaceutical equipment and other links; promote the orderly transfer of industries in China, and optimize the layout of regional industrial chains.

Fourth, the industrial structure has been significantly optimized, the integration of production capacity has been further accelerated, the proportion of the main business income of the top 100 enterprises has increased significantly, and some pharmaceutical enterprises have entered the forefront of global pharmaceutical enterprises.. The key tasks are to raise the threshold of industry access, promote industry reorganization and integration, guide the development of industrial agglomeration, and support the development of producer services.

Fifth, the green development level of the API industry has been improved, and the outstanding problems restricting the development of the industry such as hazardous waste management and VOCS emission have been interpreted and solved. The green manufacturing level of API has been improved, and the development and application of cleaner production technology has been further promoted. API production is concentrated to advantageous enterprises, forming a number of high-level API green development parks.. The key tasks are to adjust the industrial structure, optimize the industrial layout, accelerate technological innovation and application, and implement green production standards.

Sixth, the level of advanced manufacturing has continued to improve, the application of advanced manufacturing technology in enterprises has increased, the production efficiency and scale of factories have improved, and the continuous, digital, intelligent and integrated level of the pharmaceutical process has improved, creating a number of world-class benchmark factories.The key task is to improve the level of informatization and intelligent manufacturing in the whole industry, promote enterprises to implement digital transformation in R & D and design, production and manufacturing, logistics and warehousing, operation and management around the two key points of "quality and efficiency", improve quality control, improve production and operation efficiency and reduce production costs. Improve the level of safety management, and promote enterprises to establish a scientific, systematic, proactive, advanced and comprehensive accident prevention system from the "intrinsic safety.

Seventh, the internationalization strategy was further implemented, and the average annual growth rate of pharmaceutical exports maintained medium-to-high growth.The proportion of pharmaceutical preparations and medium and high-end medical equipment exports increased, and the international market sales of innovative drugs formed a scale.. The key task is to increase the number of generic drugs registered in developed countries in Europe and the United States, and improve the technical content and added value. Accelerate the promotion of a number of overseas clinical research projects that have entered the third phase of 2., and achieve more breakthroughs in the international registration of domestic innovative drugs as soon as possible.